Ocugen is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Kelly Beck, MBA, SPHR, SHRM-SCP, PMP
VP, Investor Relations & Administration
Phone: +1 (484) 328-4698